Cited by 90Advanced Glycation End Products researchDiabetes, Cardiovascular Risks, and LipoproteinsNitric Oxide and Endothelin Effects

Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study

Open access
Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C., Bahn, Gideon, Beisswenger, Paul J., Reaven, Peter D., for the VADT Investigators·2017·Diabetes Care

Abstract

OBJECTIVE: To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study. RESEARCH DESIGN AND METHODS: Baseline plasma levels of methylglyoxal hydroimidazolone, Nε-carboxymethyl lysine, Nε-carboxyethyl lysine (CEL), 3-deoxyglucosone hydroimidazolone and glyoxal hydroimidazolone (G-H1), 2-aminoadipic acid (2-AAA), and methionine sulfoxide were measured in a total of 411 participants, who underwent ultrasound assessment of carotid intima-media thickness (CIMT), and computed tomography scanning of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) after an average of 10 years of follow-up. RESULTS: In risk factor–adjusted multivariable regression models, G-H1 was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis. CONCLUSIONS: Specific advanced glycation end products and metabolic oxidation products are associated with the severity of subclinical atherosclerosis over the long term and may play an important role in the “negative metabolic memory” of macrovascular complications in people with long-standing T2D.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc16-1875

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Higher levels of circulating AGEs are positively correlated with the incidence of cardiovascular disorders and severity of coronary atherosclerosis and coronary artery disease independent of diabetic status.

    “Additionally, higher levels of circulating AGEs are positively correlated with the incidence of cardiovascular disorders and severity of coronary atherosclerosis and coronary artery disease independent of diabetic status62–64, suggesting a causal role of AGEs in cardiovascular diseases.”
  • AGEs have a causal role in cardiovascular diseases.

    “Additionally, higher levels of circulating AGEs are positively correlated with the incidence of cardiovascular disorders and severity of coronary atherosclerosis and coronary artery disease independent of diabetic status62–64, suggesting a causal role of AGEs in cardiovascular diseases.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Saremi, A., Howell, S., Schwenke, D. C., Bahn, G., Beisswenger, P. J., Reaven, P. D., & for the VADT Investigators
Affiliations
  • Phoenix VA Health Care System (US)
  • PreventAGE Health Care (United States) (US)
  • Cooperative Studies Program Coordinating Center, Hines, IL
Corresponding author
  • Saremi, Aramesh
  • Reaven, Peter D.
Venue
Diabetes Care
Published
2017-02-01
Volume
40
Issue
4
Pages
591-598
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2584038420
Cited by
90
References
41
Citations by year
2026: 3 · 2025: 8 · 2024: 5 · 2023: 15 · 2022: 11 · 2021: 12 · 2020: 11 · 2019: 10 · 2018: 12 · 2017: 3
FWCI
8.19
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Veterans Affairs Cooperative Studies Program of the U.S. Department of Veterans Affairs Office of Research and Development
  • National Institutes of Health (R01-067690, 5R01-094775)
  • American Diabetes Association
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
Keywords
advanced glycation end products, oxidative stress, type 2 diabetes, subclinical atherosclerosis, carotid intima-media thickness, coronary artery calcification, abdominal aortic calcification, 2-aminoadipic acid, Nε-(carboxyethyl)lysine, carboxymethyllysine, methionine sulfoxide, macrovascular complications
MeSH terms
Aged, Blood Glucose, Cholesterol, Deoxyglucose, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Imidazoles, Lysine, Male, Middle Aged, Oxidation-Reduction, Pyruvaldehyde, Triglycerides, Glycation End Products, Advanced, Atherosclerosis, Carotid Intima-Media Thickness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review